Edition:
United States

ImmunoGen Inc (IMGN.O)

IMGN.O on Nasdaq

1.88USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$1.88
Open
--
Day's High
--
Day's Low
--
Volume
600
Avg. Vol
1,275,564
52-wk High
$14.10
52-wk Low
$1.51

IMGN.O

Chart for IMGN.O

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target... (more)

Overall

Beta: 2.11
Market Cap(Mil.): $181.59
Shares Outstanding(Mil.): 87.30
Dividend: --
Yield (%): --

Financials

  IMGN.O Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.79 -- --
ROI: -73.36 -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer

* Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer

Nov 11 2016

BRIEF-Immunogen CFO Johnston buys 10,000 shares of co's common stock on Nov 2

* Immunogen Inc CFO David Johnston reports open market purchase of 10,000 shares of co's common stock on Nov 2 at $1.70per share Source text: (http://bit.ly/2e5xpJI) Further company coverage:

Nov 03 2016

BRIEF-Immunogen quarterly loss $0.51 per share

* Immunogen reports financial results for quarter ended September 30 and reviews business highlights

Oct 28 2016

BRIEF-Immunogen: Will reduce workforce by 17 pct

* Company will reduce its workforce by 17 pct and seek to partner its non-core b-cell lymphoma programs

Sep 29 2016

BRIEF-Immunogen announces update to financial results year ended June 30, 2016 - SEC filing

* Announces update to financial results for the quarter and year ended June 30, 2016 - SEC filing

Aug 25 2016

BRIEF-Immunogen reports departure of chief development officer

* Immunogen announces departure of chief development officer Source text for Eikon: Further company coverage:

Aug 09 2016

BRIEF-Immunogen Q4 loss per share $0.51

* Immunogen reports fourth quarter and fiscal year 2016 financial results and provides quarterly business update

Aug 04 2016

BRIEF-ImmunoGen announces pricing of $100 mln offering of Senior Notes

* Sale of notes is expected to result in $96.7 million net proceeds to Immunogen

Jun 15 2016

BRIEF-Immunogen announces proposed $100 mln offering of convertible senior notes

* Immunogen announces proposed $100 million offering of convertible senior notes due 2021

Jun 13 2016

Earnings vs. Estimates